Gynecologic Cancer Care: Innovative Progress PDF Download

Author: Carolyn Y. Muller
Publisher: Elsevier Health Sciences
ISBN: 0323655394
Category : Medical
Languages : en
Pages :

View

Book Description
In consultation with Dr. William Rayburn, Dr. Muller has put together an issue designed to educate the reader on the rapid progress in Gynecologic Cancer Care. More than any other field in obstetrics and gynecology, gynecologic oncology has seen an explosion in integrated drug development and technology, including personalized medicine, germline and somatic testing, targeted therapeutics, biologic and immunotherapies, improved robotic technology, and a paradigm shift towards “less is more. Evolving data in quality measures including enhanced surgical recovery, integrative palliative care, and survivorship management has strengthened the need for a seemless team approach to the care of our patients. Despite the complexity and rapid discoveries leading to significant change in practice, the dedication to patients is the driver to stay up to date and participate in the research and clinical trials that lead to the cancer care advances that are substantial in this update. Expert authors have contributed articles on the following topics: Trends in Gynecologic Cancer Care in North America: Safety, Value and Quality; Cancer Screening and Prevention Highlights in Gynecologic Cancer; Germline and Somatic Tumor Testing in Gynecologic Cancer Care; Less is More: Minimally Invasive and Quality Surgical Management of Gynecologic Cancer; Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management; Endometrial Cancer: Obesity, Genetics and Targeted Trials; Cervical Cancer: A Global and Access to Care Crisis; Vulvar and Vaginal Cancer; Gestational Trophoblastic Neoplasia; Chemotherapy, Biologic and Immunotherapy Breakthroughs in Cancer Care; Palliative Care in Gynecologic Oncology; Personalized Medicine in Gynecologic Cancer: Fact or Fiction; and Survivorship Care in Gynecologic Cancer.

Author:
Publisher:
ISBN:
Category : Generative organs, Female
Languages : en
Pages : 130

View

Book Description

Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309380499
Category : Medical
Languages : en
Pages : 397

View

Book Description
In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.

Author:
Publisher: Elsevier
ISBN: 012824299X
Category : Science
Languages : en
Pages : 388

View

Book Description
Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers

Author: Patricia J. Eifel
Publisher: Springer Science & Business Media
ISBN: 9780387287942
Category : Medical
Languages : en
Pages : 340

View

Book Description
Gynecologic cancer includes cancer of the female lower genital tract: vagina, vulva, cervix, endometrium, uterus, and ovaries. Gynecologic Cancer is the fourth volume in the M.D. Anderson Cancer Care Series, featuring the current standard approach to gynecologic cancer care from the experts at M.D. Anderson Cancer Center. Designed for the practicing oncologist, this clinical guidebook allows for quick, authoritative access to the latest and best multimodality therapies. Topics covered in this volume include primary prevention and early detection, preinvasive diseases of female lower genital tract, pathology and imaging of gynecologica malignancies, treatment of vaginal, cervical, endometrial, uterine cancers. Discussions also address fertility-sparing options for treatment of women with gynecologica cancers as well as sexuality in women with gyn malignancies. Each of the 20 chapters ends with an up-to-date list of suggested readings, as well as "key practice points" highlighting the most principles and practices of each chapter for at-a-glance reference. More than 80 illustrations complement the text. This thorough, practical volume is the essential clinical guide for the oncologists, surgeons, and all physicians involved in the care of patients with gynecologic cancer.

Author: Galina Velikova
Publisher: EBN Health, an imprint of Evidence-based Networks Ltd
ISBN: 0995595410
Category : Medical
Languages : en
Pages : 220

View

Book Description
Winner of the BMA Oncology Book of the Year Award. The authors provide a compendium of best practice, including 25 case studies to act as models for professionals to make decisions, either for individual patients or as the basis for policy across an organisation, planning area, region or country. This guide is designed as a handbook for practising clinicians and professionals. It is also an excellent training tool, which will help new teams and clinical staff to align thinking, develop procedures, and adopt best practice.

Author: National Academies Of Sciences Engineeri
Publisher: National Academies Press
ISBN: 9780309136594
Category : Medical
Languages : en
Pages :

View

Book Description
New technologies and improved understanding of the genesis and progression of various cancers have added to the enthusiasm for potential new strategies to improve screening and early detection of cancer. Research is also under way to evaluate refinements in current screening approaches, including determining optimal screening intervals, the ages at which screening should begin and end, as well as more specific estimates of the potential risks and benefits of screening for certain populations, such as racial and ethnic minority populations and people who have elevated risk for specific cancers. However, there remain significant challenges to developing, validating, and effectively implementing new cancer screening approaches. Guidelines for screening issued by different organizations vary considerably with no clear way of deciding which guidelines are most trustworthy. There is also a need to improve access to high-quality cancer screening and follow-up care, particularly in low-resource communities and among populations who are underserved or have numerous barriers to receiving care. Â To examine the challenges and opportunities related to improving current approaches to cancer screening, as well as the evidence base for novel cancer screening methods, the National Cancer Policy Forum held a workshop, Advancing Progress in the Development and Implementation of Effective, High-Quality Cancer Screening, on March 2-3, 2020, in Washington, DC. This workshop convened a broad range of experts, including clinicians, researchers, statisticians, and patient advocates, as well as representatives of health care organizations, academic medical centers, insurers, and federal agencies. This publication summarizes the presentations and discussions of the workshop and highlights suggestions from individual participants regarding how to improve cancer screening.

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 030906497X
Category : Medical
Languages : en
Pages : 304

View

Book Description
America's Health Care Safety Net explains how competition and cost issues in today's health care marketplace are posing major challenges to continued access to care for America's poor and uninsured. At a time when policymakers and providers are urgently seeking guidance, the committee recommends concrete strategies for maintaining the viability of the safety netâ€"with innovative approaches to building public attention, developing better tools for tracking the problem, and designing effective interventions. This book examines the health care safety net from the perspectives of key providers and the populations they serve, including: Components of the safety netâ€"public hospitals, community clinics, local health departments, and federal and state programs. Mounting pressures on the systemâ€"rising numbers of uninsured patients, decline in Medicaid eligibility due to welfare reform, increasing health care access barriers for minority and immigrant populations, and more. Specific consequences for providers and their patients from the competitive, managed care environmentâ€"detailing the evolution and impact of Medicaid managed care. Key issues highlighted in four populationsâ€"children with special needs, people with serious mental illness, people with HIV/AIDS, and the homeless.

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 030926944X
Category : Medical
Languages : en
Pages : 95

View

Book Description
Rising health care costs are a central fiscal challenge confronting the United States. National spending on health care currently accounts for 18 percent of gross domestic product (GDP), but is anticipated to increase to 25 percent of GDP by 2037. The Bipartisan Policy Center argues that "this rapid growth in health expenditures creates an unsustainable burden on America's economy, with far-reaching consequences". These consequences include crowding out many national priorities, including investments in education, infrastructure, and research; stagnation of employee wages; and decreased international competitiveness.In spite of health care costs that far exceed those of other countries, health outcomes in the United States are not considerably better. With the goal of ensuring that patients have access to high-quality, affordable cancer care, the Institute of Medicine's (IOM's) National Cancer Policy Forum convened a public workshop, Delivering Affordable Cancer Care in the 21st Century, October 8-9, 2012, in Washington, DC. Delivering Affordable Cancer Care in the 21st Century summarizes the workshop.

Author: Rebecca Skloot
Publisher: Crown
ISBN: 0307589382
Category : Science
Languages : en
Pages : 386

View

Book Description
#1 NEW YORK TIMES BESTSELLER • “The story of modern medicine and bioethics—and, indeed, race relations—is refracted beautifully, and movingly.”—Entertainment Weekly NOW A MAJOR MOTION PICTURE FROM HBO® STARRING OPRAH WINFREY AND ROSE BYRNE • ONE OF THE “MOST INFLUENTIAL” (CNN), “DEFINING” (LITHUB), AND “BEST” (THE PHILADELPHIA INQUIRER) BOOKS OF THE DECADE • ONE OF ESSENCE’S 50 MOST IMPACTFUL BLACK BOOKS OF THE PAST 50 YEARS • WINNER OF THE CHICAGO TRIBUNE HEARTLAND PRIZE FOR NONFICTION NAMED ONE OF THE BEST BOOKS OF THE YEAR BY The New York Times Book Review • Entertainment Weekly • O: The Oprah Magazine • NPR • Financial Times • New York • Independent (U.K.) • Times (U.K.) • Publishers Weekly • Library Journal • Kirkus Reviews • Booklist • Globe and Mail Her name was Henrietta Lacks, but scientists know her as HeLa. She was a poor Southern tobacco farmer who worked the same land as her slave ancestors, yet her cells—taken without her knowledge—became one of the most important tools in medicine: The first “immortal” human cells grown in culture, which are still alive today, though she has been dead for more than sixty years. HeLa cells were vital for developing the polio vaccine; uncovered secrets of cancer, viruses, and the atom bomb’s effects; helped lead to important advances like in vitro fertilization, cloning, and gene mapping; and have been bought and sold by the billions. Yet Henrietta Lacks remains virtually unknown, buried in an unmarked grave. Henrietta’s family did not learn of her “immortality” until more than twenty years after her death, when scientists investigating HeLa began using her husband and children in research without informed consent. And though the cells had launched a multimillion-dollar industry that sells human biological materials, her family never saw any of the profits. As Rebecca Skloot so brilliantly shows, the story of the Lacks family—past and present—is inextricably connected to the dark history of experimentation on African Americans, the birth of bioethics, and the legal battles over whether we control the stuff we are made of. Over the decade it took to uncover this story, Rebecca became enmeshed in the lives of the Lacks family—especially Henrietta’s daughter Deborah. Deborah was consumed with questions: Had scientists cloned her mother? Had they killed her to harvest her cells? And if her mother was so important to medicine, why couldn’t her children afford health insurance? Intimate in feeling, astonishing in scope, and impossible to put down, The Immortal Life of Henrietta Lacks captures the beauty and drama of scientific discovery, as well as its human consequences.